Acute Porphyria Drug Database

V08CA03 - Gadodiamide
Not porphyrinogenic
NP

Rationale
Gadodiamide is excreted unchanged though the kidneys.
Chemical description
Gadodiamide is a nonionic gadolinium chelate.
Therapeutic characteristics
Gadodiamide is used as a magnetic resonance contrast medium. It is administered intravenously. Nausea is a common adverse reaction of gadodiamide that can be confused with an acute porphyric attack.
Hepatic exposure
Not relevant.
Metabolism and pharmakokinetics
Gadodiamide is rapidly distributed into extracellular fluid. About 96% of a dose is excreted unchanged in the urine within 24 hours. No metabolites have been found.

References

  1. Drug reference publications
  2. Sweetman SC, editor. Martindale: The complete drug reference. Gadodiamide. Pharmaceutical Press 2009. #2968
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). Omniscan. #2967

Similar drugs
Explore alternative drugs in similar therapeutic classes V08C / V08CA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙